Additional file 1: of Influence of upper and temporal transconjunctival sclerocorneal incision on marginal reflex distance after cataract surgery

Preoperative and postoperative MRD1 values, and preoperative distance between medial and lateral canthi. (XLSX 13 kb

Effect of compound C on bupivacaine-induced AMPK and p38 MAPK activity.

<p>Neuro2a cells were treated with AMPK inhibitor compound C (10 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). *<i>P</i><0.05, **<i>P</i><0.01 and ***<i>P</i><0.001 vs. control (not treated with bupivacaine), ^#<i>P</i><0.05, ^##<i>P</i><0.01 and ^###<i>P</i><0.001 vs. absence of compound C. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including compound C group and time period as factors and the interaction term between the two factors.</p

Schematic diagram illustrating the proposed signaling pathway involved in bupivacaine-induced WDR35 expression in Neuro2a cells.

<p>Schematic diagram illustrating the proposed signaling pathway involved in bupivacaine-induced WDR35 expression in Neuro2a cells.</p

Effect of bupivacaine on intracellular ATP levels and AMPK activation.

<p>Neuro2a cells were treated with 2(A) Intracellular levels of ATP were measured with a luminescence assay (n = 4 per group). (B) Expression of phospho-AMPKα (P-AMPKα) and AMPK following cell exposure to bupivacaine was measured by Western blotting (n = 3 per group). ***<i>P</i><0.001 vs. control (not treated with bupivacaine). All post hoc pairwise comparisons were performed by Tukey's test with repeated measures one-way ANOVA.</p

Effect of STO-609 on bupivacaine-induced AMPK and p38 MAPK activity.

<p>Neuro2a cells were treated with CaMKK inhibitor STO-609 (50 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). **<i>P</i><0.01 and ***<i>P</i><0.001 vs. control (not treated with bupivacaine), ^##<i>P</i><0.01 and ^###<i>P</i><0.001 vs. absence of STO-609. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including STO-609 group and time period as factors and the interaction term between the two factors.</p

The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0267-2"><b>here</b>.</a><br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides<u></u></p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p

Effect of compound C and iodotubercidin on bupivacaine-induced WDR35 expression.

<p>(A) Neuro2a cells were treated with various concentrations of compound C for 1 h, followed by bupivacaine (2 mM) for 9 h. WDR35 mRNA expression was analyzed by qPCR and expressed relative to the level of β-actin mRNA (n = 4 per group). All post hoc comparisons were performed by Tukey's test with one-way ANOVA. (B) WDR35 protein expression with or without 10 µM compound C was analyzed by Western blotting (n = 4 per group). All post hoc comparisons were performed by Tukey's test with two-way ANOVA including bupivacaine and compound C groups as factors and the interaction term between the two factors. (C) Cells were treated with various concentrations of iodotubercidin for 1 h, followed by bupivacaine (2 mM) for 9 h. WDR35 mRNA expression was analyzed by qPCR (n = 4 per group). All post hoc comparisons were performed by Tukey's test with one-way ANOVA. (D) WDR35 protein expression with or without 1 µM iodotubercidin was analyzed by Western blotting (n = 3 per group). All post hoc comparisons were performed by Tukey's test with two-way ANOVA including bupivacaine and iodotubercidin groups as factors and the interaction term between the two factors. **<i>P</i><0.01 and ***<i>P</i><0.001 vs. control (not treated with bupivacaine), ^#<i>P</i><0.05 and ^###<i>P</i><0.001 vs. treatment with bupivacaine alone.</p

Effect of iodotubercidin on bupivacaine-induced AMPK and p38 MAPK activity.

<p>Neuro2a cells were treated with AMPK inhibitor iodotubercidin (1 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). *<i>P</i><0.05, **<i>P</i><0.01 and ***<i>P</i><0.001 vs. control (not treated with bupivacaine), ^#<i>P</i><0.05, ^##<i>P</i><0.01 and ^###<i>P</i><0.001 vs. absence of iodotubercidin. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including iodotubercidin group and time period as factors and the interaction term between the two factors.</p

Effect of STO-609 on bupivacaine-induced WDR35 expression.

<p>(A) Neuro2a cells were treated with various concentrations of STO-609 for 1 h, followed by bupivacaine (2 mM) for 9 h. WDR35 mRNA expression was analyzed by qPCR and expressed relative to the level of β-actin mRNA (n = 4 per group). All post hoc comparisons were performed by Tukey's test with one-way ANOVA. (B) WDR35 protein expression with or without 50 µM STO-609 was analyzed by Western blotting (n = 3 per group). All post hoc comparisons were performed by Tukey's test with two-way ANOVA including bupivacaine and STO-609 groups as factors and the interaction term between the two factors. **<i>P</i><0.01 and ***<i>P</i><0.001 vs. control (not treated with bupivacaine), ^##<i>P</i><0.01 and ^###<i>P</i><0.001 vs. absence of STO-609.</p

Characteristics according to quintile categories of type 1 life style pattern score.

<p>Characteristics according to quintile categories of type 1 life style pattern score.</p